KR20120104517A - 류마티스 관절염의 치료, 진단 및 모니터링 방법 - Google Patents

류마티스 관절염의 치료, 진단 및 모니터링 방법 Download PDF

Info

Publication number
KR20120104517A
KR20120104517A KR1020127008453A KR20127008453A KR20120104517A KR 20120104517 A KR20120104517 A KR 20120104517A KR 1020127008453 A KR1020127008453 A KR 1020127008453A KR 20127008453 A KR20127008453 A KR 20127008453A KR 20120104517 A KR20120104517 A KR 20120104517A
Authority
KR
South Korea
Prior art keywords
combination
genes
subtype
expression
serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127008453A
Other languages
English (en)
Korean (ko)
Inventor
제이알. 글린 데니스
플라비우스 마틴
마이클 제이. 타운센드
Original Assignee
제넨테크, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제넨테크, 인크. filed Critical 제넨테크, 인크.
Publication of KR20120104517A publication Critical patent/KR20120104517A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Rehabilitation Therapy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
KR1020127008453A 2009-09-03 2010-09-02 류마티스 관절염의 치료, 진단 및 모니터링 방법 Ceased KR20120104517A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US27594809P 2009-09-03 2009-09-03
US61/275,948 2009-09-03
US25242409P 2009-10-16 2009-10-16
US61/252,424 2009-10-16

Publications (1)

Publication Number Publication Date
KR20120104517A true KR20120104517A (ko) 2012-09-21

Family

ID=43625246

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127008453A Ceased KR20120104517A (ko) 2009-09-03 2010-09-02 류마티스 관절염의 치료, 진단 및 모니터링 방법

Country Status (11)

Country Link
US (2) US8728730B2 (enExample)
EP (2) EP3211094A3 (enExample)
JP (3) JP5996429B2 (enExample)
KR (1) KR20120104517A (enExample)
CN (2) CN102597268B (enExample)
BR (1) BR112012004777A2 (enExample)
CA (1) CA2772929A1 (enExample)
IN (1) IN2012DN02485A (enExample)
MX (2) MX2012002766A (enExample)
RU (2) RU2539112C2 (enExample)
WO (1) WO2011028945A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014204274A1 (ko) * 2013-06-21 2014-12-24 가톨릭대학교 산학협력단 류마티스 관절염 진단 또는 활성도 평가용 바이오마커
KR20150031405A (ko) * 2013-09-13 2015-03-24 인제대학교 산학협력단 Ｖｓｉｇ４를 이용한 난소암 치료제 스크리닝 방법
WO2016064229A1 (ko) * 2014-10-24 2016-04-28 가톨릭대학교 산학협력단 류마티스 관절염 관련 바이오마커
KR20180052104A (ko) * 2016-11-09 2018-05-17 아이씨엠 주식회사 Nkx3.2 단편을 유효성분으로 포함하는 관절염의 예방 또는 치료용 약학 조성물
KR20200086627A (ko) * 2017-11-13 2020-07-17 더 멀티플 마이얼로머 리서치 파운데이션, 인크. 통합된, 분자, 체학, 면역요법, 대사, 후성적, 및 임상 데이터베이스
KR20210055856A (ko) * 2019-11-07 2021-05-18 가톨릭대학교 산학협력단 류마티스 관절염의 판누스 진단용 바이오마커 및 이의 이용

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201809892T4 (tr) 2003-11-05 2018-07-23 Roche Glycart Ag Fc reseptörüne bağlanma afinitesi ve artırılmış efektör fonksiyonu bulunan antijen bağlayan moleküller.
US8645166B2 (en) 2007-07-16 2014-02-04 Russell W. Bessette System and method for scoring illness complexity to predict healthcare cost
TW201438738A (zh) 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
MX2012002766A (es) 2009-09-03 2012-04-02 Genentech Inc Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.
JP5947727B2 (ja) 2010-01-20 2016-07-06 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗ｉｌｔ５抗体およびｉｌｔ５結合抗体断片による免疫調節
US9023997B2 (en) 2010-01-20 2015-05-05 Merck Sharp & Dohme Corp. Anti-ILT5 antibodies and ILT5-binding antibody fragments
EP2538973A2 (en) 2010-02-26 2013-01-02 Novo Nordisk A/S Stable antibody containing compositions
PE20130206A1 (es) 2010-05-06 2013-02-28 Novartis Ag Anticuerpos multivalentes antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones
WO2011138392A1 (en) 2010-05-06 2011-11-10 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
US20130136733A1 (en) 2010-05-28 2013-05-30 Novo Nordisk A/S Stable Multi-Dose Compositions Comprising an Antibody and a Preservative
CA3211246A1 (en) 2010-12-06 2012-06-14 Seagen Inc. Humanized antibodies to liv-1 and use of same to treat cancer
JP5885926B2 (ja) * 2011-01-28 2016-03-16 シスメックス株式会社 関節リウマチの存在の評価方法およびその方法に用いられるバイオマーカーセット
WO2012118750A2 (en) 2011-02-28 2012-09-07 Genentech, Inc. Biological markers and methods for predicting response to b-cell antagonists
US8883735B2 (en) 2011-11-04 2014-11-11 Novartis Ag Low density lipoprotein-related protein 6 (LRP6)-half life extender constructs
CN104204230A (zh) 2012-02-10 2014-12-10 诺和诺德A/S（股份有限公司） 治疗炎性疾病和病症的相关方法
WO2013135789A1 (en) * 2012-03-15 2013-09-19 Universiteit Hasselt Means and methods for the determination of the joint destruction progression rate in rheumatoid arthritis patients
WO2013164440A1 (en) 2012-05-03 2013-11-07 Novo Nordisk A/S Methods related to treatment of inflammatory diseases and disorders
WO2014028374A1 (en) * 2012-08-17 2014-02-20 Eli Lilly And Company Biomarkers predictive of rheumatoid arthritis or systemic lupus erythematosus response to anti-baff antibody therapy
EP2951586A1 (en) * 2013-01-31 2015-12-09 The University of Birmingham Biomarkers of autoimmune and/or chronic diseases associated with joint inflammation
EP2813850A1 (en) * 2013-06-10 2014-12-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting rheumatoid arthritis treatment response
TWI725931B (zh) 2013-06-24 2021-05-01 美商建南德克公司 抗ｆｃｒｈ５抗體
CN103399147B (zh) * 2013-08-07 2015-06-17 苏州大学 多聚半乳糖醛酸的新应用
CN103513040B (zh) * 2013-10-16 2015-03-11 常晓天 蛋白cd38在制备类风湿性关节炎诊断标记物中的应用
EP2863231A1 (en) * 2013-10-17 2015-04-22 Institut D'Investigaciones Biomédiques August Pi i Sunyer Diagnostic method for detecting a GABA(A) related autoimmune disease and related subject-matter
AU2015229270B2 (en) 2014-03-12 2020-12-24 Icahn School Of Medicine At Mount Sinai Method for identifying kidney allograft recipients at risk for chronic injury
RU2554755C1 (ru) * 2014-05-26 2015-06-27 Федеральное бюджетное учреждение науки "Санкт-Петербургский научно-исследовательский институт эпидемиологии и микробиологии им. Пастера" (ФБУН НИИ эпидемиологии и микробиологии имени Пастера) Способ диагностики ревматоидного артрита
CN106661635B (zh) 2014-06-26 2021-05-28 西奈山伊坎医学院 通过分析预示性基因集诊断亚临床和临床的急性排异的方法
CN107209177A (zh) 2015-01-29 2017-09-26 阿雷斯贸易股份有限公司 用于高正电荷蛋白的免疫测定法
CN105988009B (zh) * 2015-02-28 2018-03-13 复旦大学附属华山医院 Netrin‑4在制备检测胃癌及预后标志物的制剂中的用途
WO2016154553A1 (en) * 2015-03-25 2016-09-29 La Jolla Institute For Allergy And Immunology Cxcl13 as an indicator of germinal center activity and immune response
CA2985637A1 (en) * 2015-05-12 2016-11-17 The General Hospital Corporation Autoantigens for diagnosis of rheumatoid arthritis
CN107849132B (zh) 2015-06-16 2022-03-08 豪夫迈·罗氏有限公司 人源化的和亲和力成熟的针对FcRH5的抗体和使用方法
CN105200159B (zh) * 2015-11-06 2018-06-15 北京致成生物医学科技有限公司 骨性关节炎诊疗试剂及其应用
GB201521357D0 (en) * 2015-12-03 2016-01-20 Univ Liverpool Methods for predicting response to anti-TNF therapy
MA45324A (fr) 2016-03-15 2019-01-23 Seattle Genetics Inc Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique
US11644473B2 (en) * 2016-04-15 2023-05-09 Rowan University Serum biomarkers for predicting and evaluating response to TNF inhibitor therapy in rheumatoid arthritis patients
US20170321286A1 (en) 2016-05-05 2017-11-09 Exact Sciences Corporation Detection of lung neoplasia by amplification of rna sequences
WO2017214180A1 (en) 2016-06-07 2017-12-14 The General Hospital Corporation Identification of a t cell epitope of prevotella copri that induces t cell responses in patients with rheumatoid arthritis
RU2622597C1 (ru) * 2016-07-05 2017-06-16 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кубанский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО КубГМУ Минздрава России) Способ прогнозирования суставного болевого синдрома у пациентов с признаками дисплазии соединительной ткани
GB201616557D0 (en) * 2016-09-29 2016-11-16 Secretary Of State For Health The Assay for distinguishing between sepsis and systemic inflammatory response syndrome
CN106526196B (zh) * 2016-10-08 2018-08-10 北京大学人民医院 Sr-a作为类风湿关节炎诊断标志物及干预靶点的应用
CN109923128A (zh) 2016-11-15 2019-06-21 基因泰克公司 用于用抗cd20/抗cd3双特异性抗体进行治疗的给药
WO2018164507A2 (ko) * 2017-03-08 2018-09-13 주식회사 길로 Mast4 유전자를 이용한 세포외 기질 생산용 조성물 및 그 제조방법
KR102588627B1 (ko) * 2017-03-08 2023-10-16 김성진 Mast4 유전자를 이용한 세포외 기질 생산용 조성물 및 그 제조방법
CA3074126A1 (en) * 2017-08-29 2019-03-07 Veritas Therapeutics Inc. Fgl2 antibodies and binding fragments thereof and uses thereof
EP4502182A3 (en) * 2018-01-24 2025-07-09 Genentech, Inc. Diagnostic and therapeutic methods for the treatment of rheumatoid arthritis (ra)
CN108359726B (zh) * 2018-02-28 2020-09-04 固安博健生物技术有限公司 Coro2b作为分子诊治标志物的用途
WO2019178546A1 (en) 2018-03-16 2019-09-19 Scipher Medicine Corporation Methods and systems for predicting response to anti-tnf therapies
BR112020019972A2 (pt) 2018-04-16 2021-01-05 Icahn School Of Medicine At Mount Sinai Métodos para identificar um receptor de aloenxerto renal e para identificar um receptor de aloenxerto renal em risco de rejeição aguda do aloenxerto antes do transplante, kit para identificar receptores de aloenxerto renal e método para selecionar um paciente com aloenxerto renal
US20190336585A1 (en) * 2018-05-03 2019-11-07 John Lawrence Mee Method for sustainable human cognitive enhancement
US20190359985A1 (en) * 2018-05-22 2019-11-28 John Lawrence Mee Adjustable method for sustainable human cognitive enhancement
CN109142729B (zh) * 2018-06-14 2021-04-23 郑州大学第一附属医院 一种肺癌标志物抗-hmgb3自身抗体及其应用
US20210284942A1 (en) * 2018-06-21 2021-09-16 Astraveus Microfluidic device and method for processing particles
US20190390193A1 (en) * 2018-06-23 2019-12-26 John Lawrence Mee Reversible method for sustainable human cognitive enhancement
US10723191B1 (en) 2018-07-01 2020-07-28 Softwheel Ltd. In-wheel three-arm suspension for vehicles
CN110917351A (zh) * 2018-09-20 2020-03-27 华中科技大学同济医学院附属同济医院 Mbd2抑制剂在预防和治疗纤维化疾病中的用途
EP3866835B1 (en) * 2018-10-19 2024-01-03 The Regents Of The University Of Michigan Method for monitoring autoimmune disease
CN109207584A (zh) * 2018-11-01 2019-01-15 固安博健生物技术有限公司 Marco作为早期诊断骨关节炎的分子标志物的应用
WO2020163876A1 (en) * 2019-02-08 2020-08-13 The Regents Of The University Of California Compositions and methods involving layilin
KR20220012244A (ko) 2019-04-29 2022-02-03 솔렌트 테라퓨틱스, 엘엘씨 Mrgx2의 억제제로서의 3-아미노-4h-벤조[e][1,2,4]티아디아진 1,1-디옥사이드 유도체
CA3139508A1 (en) * 2019-05-08 2020-11-12 Janssen Biotech, Inc. Materials and methods for modulating t cell mediated immunity
EP3990656A4 (en) 2019-06-27 2023-12-06 Scipher Medicine Corporation Developing classifiers for stratifying patients
CN110456074B (zh) * 2019-08-27 2022-06-03 广东菲鹏生物有限公司 瓜氨酸肽及其应用、类风湿关节炎的检测试剂与试剂盒
CN110408590B (zh) * 2019-09-06 2022-10-25 遵义医学院附属医院 一种诱导人间充质干细胞向成骨细胞分化的方法与应用
GB201914079D0 (en) * 2019-09-30 2019-11-13 Univ London Queen Mary Method of predicting requirement for biologic therapy
CN111091909B (zh) * 2019-11-26 2022-05-31 中国信息通信研究院 一种医学影像识别方法和装置
CN113122628B (zh) * 2019-12-30 2023-08-11 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） Clec5a基因作为标志物在子宫内膜癌中诊断及治疗的应用
CN112114126B (zh) * 2020-08-13 2023-03-24 川北医学院 一种系统性红斑狼疮的诊断标志物及其应用
WO2022064163A1 (en) * 2020-09-22 2022-03-31 The Secretary Of State For Defence Apparatus, kits and methods for predicting the development of sepsis
EP4237003A4 (en) 2020-10-28 2025-07-09 Janssen Biotech Inc COMPOSITIONS AND METHODS FOR MODULATING GAMMA DELTA CHAIN-MEDIATED IMMUNITY
WO2022098638A2 (en) 2020-11-04 2022-05-12 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
MX2023005130A (es) 2020-11-04 2023-05-25 Genentech Inc Dosis subcutanea de anticuerpos biespecificos anti-cd20/anti-cd3.
CN112646887B (zh) * 2020-12-23 2023-02-28 广州医科大学附属第五医院 Znf239作为肝癌诊治的靶标
CN112946269B (zh) * 2020-12-29 2022-12-27 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） Abca1与cd68作为预后标记物在制备肝癌预后预测试剂盒中的应用
CN113186281B (zh) * 2021-04-02 2023-02-28 广州医科大学附属第五医院 作为肝细胞癌标志物的inava
CN113512582A (zh) * 2021-04-15 2021-10-19 上海鸿准生物医药科技有限公司 Slc22a18在过敏变态反应性疾病与炎症性疾病中的应用
CN113307835B (zh) * 2021-04-21 2022-12-13 南通大学 一种siRNA及其在制备慢性疼痛治疗药物中的应用
EP4330282A1 (en) 2021-04-30 2024-03-06 F. Hoffmann-La Roche AG Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
KR20240007171A (ko) 2021-05-14 2024-01-16 제넨테크, 인크. 모수네투주맙 및 폴라투주맙 베도틴을 이용한 cd20 양성 증식성 장애의 치료 방법
EP4356136A4 (en) * 2021-06-13 2025-07-30 Technion Res & Dev Foundation METHOD FOR DETERMINING SUITABILITY FOR ANTI-TNF ALPHA THERAPY
EP4479973A1 (en) * 2022-02-16 2024-12-25 Ampel Biosolutions, LLC Unsupervised machine learning methods
CN114994327B (zh) * 2022-04-12 2025-04-15 浙江大学医学院附属第二医院 一种生物标志物gsdme的应用
EP4619005A2 (en) * 2022-11-18 2025-09-24 The United States Government As Represented By The Department Of Veterans Affairs Methods for treating rheumatoid arthritis using a syndecan-1 inhibitor or a syntenin-1 inhibitor
CN116144761A (zh) * 2023-02-24 2023-05-23 山西医科大学 一种类风湿性关节炎诊断分类器的构建方法及其应用
CN116064784A (zh) * 2023-03-23 2023-05-05 上海市光华中西医结合医院 Fgf10在制备检测类风湿性关节炎试剂盒中的应用
JP2024179174A (ja) * 2023-06-14 2024-12-26 シスメックス株式会社 膜性腎症患者に対する化学療法の奏効性に関する情報を取得する方法、膜性腎症患者に対する化学療法の奏効性の判定を補助する方法及び試薬キット
CN117567626B (zh) * 2024-01-15 2024-04-26 北京大学人民医院 一种抗瓜氨酸化清道夫受体a多肽抗体及其在制备诊断类风湿关节炎的产品中的应用
WO2025218746A1 (en) * 2024-04-17 2025-10-23 Sinomab Bioscience Limited Methods of treating rheumatoid arthritis
CN119424633B (zh) * 2024-11-07 2025-07-25 浙江赛尔共银生物科技有限公司 一种包含间充质干细胞治疗退行性关节炎的组合物及其制备方法

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4434227A (en) 1982-02-08 1984-02-28 Abbott Laboratories Immunoassay for class specific immunoglobulin antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CA1261257A (en) 1984-09-19 1989-09-26 Helgi Valdimarsson Prognostic value of rheumatoid factor isotypes and their association with disease activity
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5484892A (en) 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US6139832A (en) 1995-02-08 2000-10-31 Human Genome Sciences, Inc. Leukocyte adhesion inhibitor-1 (LAI-1) Polypeptides
JPH10513355A (ja) 1995-02-08 1998-12-22 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド ヒトケモカインβ−１１およびヒトケモカインα−１
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
EP0833914A4 (en) 1995-06-05 2003-05-28 Human Genome Sciences Inc HUMAN CHEMOKINE BETA-11 AND ALPHA-1
WO1997034632A1 (en) 1996-03-20 1997-09-25 Immunomedics, Inc. Glycosylated humanized b-cell specific antibodies
CA2665133A1 (en) 1996-10-25 1998-05-07 Human Genome Sciences, Inc. Neutrokine .alpha.
ES2301183T3 (es) 1996-12-03 2008-06-16 Amgen Fremont Inc. Anticuerpo completamente humano que se une al receptor del egfr.
AU5705898A (en) 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
CA2232743A1 (en) 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5
IL134480A0 (en) 1997-09-12 2001-04-30 Apotech Sa Kay - an immune system protein and dna sequences encoding the same
DE98950411T1 (de) * 1997-10-29 2005-10-20 Otsuka Pharma Co Ltd Zusammensetzung zur Inhibierung der Proliferation glatter Muskulatur, Verfahren zur Diagnose von Arteriosklerose, sowie Kits hierzu
US6110695A (en) 1997-12-02 2000-08-29 The Regents Of The University Of California Modulating the interaction of the chemokine, B Lymphocyte Hemoattractant, and its Receptor, BLR1
WO1999033980A2 (en) 1997-12-30 1999-07-08 Chiron Corporation Members of tnf and tnfr families
DK1068241T3 (da) 1998-04-02 2008-02-04 Genentech Inc Antistofvarianter og fragmenter deraf
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PT1642972E (pt) 1999-01-07 2010-04-07 Zymogenetics Inc Utilizações terapêuticas de receptores solúveis br43x2
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR20020020730A (ko) 1999-06-09 2002-03-15 오트리브 데이비스 더블유 Ｂ-세포를 표적하는 항체를 이용한 자가면역질환의 면역치료
WO2001012812A2 (en) 1999-08-17 2001-02-22 Biogen, Inc. Baff receptor (bcma), an immunoregulatory agent
DE10041402A1 (de) 2000-08-23 2002-03-14 Morphochem Ag Neue Verbindungen, die Faktor Xa-Aktivität inhibieren
MXPA02002136A (es) * 1999-09-01 2002-09-18 Boehringer Ingelheim Pharma Metodos y composiciones para tratar una enfermedad autoinmune.
US7105149B1 (en) 1999-11-29 2006-09-12 The Trustees Of Columbia University In The City Of New York Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/myeloma
WO2001087977A2 (en) 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
KR20060088905A (ko) 2000-06-16 2006-08-07 휴먼 게놈 사이언시즈, 인코포레이티드 면역특이적으로 ＢＬｙＳ에 결합하는 항체
EP2267015A3 (en) 2000-08-18 2011-04-20 Human Genome Sciences, Inc. Binding polypeptides for B lymphocyte stimulator protein (BLyS)
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
ES2329012T3 (es) 2000-11-07 2009-11-20 Zymogenetics, Inc. Receptor del factor de necrosis tumoral humano.
EP2301971A1 (en) 2001-02-20 2011-03-30 ZymoGenetics, L.L.C. Antibodies that bind both BCMA and TACI
US6818406B2 (en) 2001-03-23 2004-11-16 Mayo Foundation For Medical Education And Research Rheumatoid arthritis markers
ATE549354T1 (de) 2001-05-11 2012-03-15 Amgen Inc Peptide und damit zusammenhängende an tall-1 bindende moleküle
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
PL377119A1 (pl) 2001-08-03 2006-01-23 Genentech, Inc. Peptydy TACIs i BR3 i ich zastosowanie
US7256015B2 (en) 2001-09-21 2007-08-14 Amgen Inc. TALL-1 receptor molecules and uses thereof
US7825089B2 (en) 2001-10-24 2010-11-02 National Jewish Health Three-dimensional structures of TALL-1 and its cognate receptors and modified proteins and methods related thereto
AU2002367732A1 (en) 2001-10-31 2003-09-09 Children's Hospital Medical Center Method for diagnosis and treatment of rheumatoid arthritis
US20030224386A1 (en) * 2001-12-19 2003-12-04 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis
KR101033196B1 (ko) 2002-02-14 2011-05-09 이뮤노메딕스, 인코오포레이티드 항-ｃｄ20 항체 및 그 융합 단백질 및 이들의 이용방법
JP2005526501A (ja) 2002-02-21 2005-09-08 デューク・ユニヴァーシティ 自己免疫疾患用の試薬および治療方法
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
BR0312767A (pt) 2002-07-18 2005-05-03 Perini Fabio Spa Unidade de armazenamento para produtos alongados
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
PT1558648E (pt) 2002-10-17 2012-04-23 Genmab As Anticorpos monoclonais humanos contra cd20
AR042485A1 (es) 2002-12-16 2005-06-22 Genentech Inc Anticuerpo humanizado que se une al cd20 humano
US6962006B2 (en) 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
SE0300959D0 (sv) 2002-12-19 2003-04-02 Pharmacia Ab Methods for predicting therapeutic response to agents acting on the growth hormone receptor
US20050163775A1 (en) 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
NZ543712A (en) 2003-06-05 2008-06-30 Genentech Inc Combination therapy for B cell disorders
IL156495A0 (en) 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
EP2280285A1 (en) 2003-09-15 2011-02-02 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose, treat, and evaluate inflammatory and autoimmune diseases
DE102004016437A1 (de) * 2004-04-04 2005-10-20 Oligene Gmbh Verfahren zur Erkennung von Signaturen in komplexen Genexpressionsprofilen
CA2501422C (en) 2004-04-29 2014-08-12 University Of Rochester Lymphoid chemokines in the diagnosis, monitoring and treatment of autoimmune disease
AR049292A1 (es) 2004-06-04 2006-07-12 Genentech Inc Metodo para tratar lupus con un anticuerpo cd20
US7999077B2 (en) 2004-09-30 2011-08-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services IRTA2 antibodies and methods of use
ZA200702335B (en) 2004-10-05 2009-05-27 Genentech Inc Method for treating vasculitis
WO2006138275A2 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20080213273A1 (en) * 2005-07-25 2008-09-04 Trubion Pharmaceuticals Inc. Single dose use of CD20-specific binding molecules
CN101262876A (zh) 2005-08-09 2008-09-10 酶遗传学股份有限公司 用taci-ig融合分子治疗b细胞恶性肿瘤的方法
WO2007038501A2 (en) 2005-09-27 2007-04-05 The Feinstein Institute For Medical Research Rheumatoid arthritis markers
CA2624359A1 (en) * 2005-09-27 2007-04-05 Source Mdx Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis
CN101405685A (zh) 2006-03-15 2009-04-08 皇家飞利浦电子股份有限公司 具有滚动检测的遥控指向技术
GB0607774D0 (en) 2006-04-20 2006-05-31 Renovo Group Plc Medicaments
EP2021016B1 (en) 2006-04-21 2016-01-06 Janssen Biotech, Inc. Cxcl-13 antagonists and tnf-alpha antagonists for use in a combination therapy
AU2007254206A1 (en) * 2006-05-16 2007-11-29 Source Mdx Assessment of effect of an agent on a human biological condition using rodent gene expression panels
EP1857559A1 (en) 2006-05-16 2007-11-21 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for predicting responsiveness to TNF alpha blocking agents
US20070269827A1 (en) * 2006-05-18 2007-11-22 Oklahoma Medical Research Foundation Predicting and Diagnosing Patients With Autoimmune Disease
WO2008156494A1 (en) * 2006-11-03 2008-12-24 The Johns Hopkins University Use of high-dose oxazaphosphorine drugs in combination with monoclonal antibodies for treating immune disorders
EP2084298A1 (en) 2006-11-09 2009-08-05 Institut National De La Sante Et De La Recherche Medicale Method for predicting therapeutic responsiveness to tnf-alpha blocking agents
US20080227704A1 (en) 2006-12-21 2008-09-18 Kamens Joanne S CXCL13 binding proteins
US20080199481A1 (en) * 2007-02-21 2008-08-21 Astrazeneca Ab Compounds
US20100273671A1 (en) 2007-03-01 2010-10-28 Universite Catholique De Louvain Method for the determination and the classification of rheumatic conditions
RU2009140047A (ru) 2007-03-30 2011-05-10 Сентокор Орто Байотек Инк. (Us) Антагонисты cхcl13 и их применение для лечения воспалительных заболеваний
CN101711286A (zh) * 2007-04-02 2010-05-19 健泰科生物技术公司 预示类风湿性关节炎对b细胞拮抗剂的响应的生物学标志物
WO2008132176A2 (en) 2007-04-27 2008-11-06 Universite Catholique De Louvain Method for evaluating the response of an individual to tnf blocking therapy
SG182183A1 (en) 2007-06-08 2012-07-30 Biogen Idec Inc Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
CA2698437A1 (en) 2007-09-03 2009-03-12 Protagen Ag Marker sequences for rheumatoid arthritis and use thereof
US20090202474A1 (en) * 2007-11-19 2009-08-13 Wyeth Expression of orphan gpr64 in inflammatory diseases
US8121883B2 (en) * 2008-02-07 2012-02-21 International Business Machines Corporation Method and system for automatically prioritizing opportunity based customer requirements
WO2010120561A1 (en) 2009-04-01 2010-10-21 Genentech, Inc. Anti-fcrh5 antibodies and immunoconjugates and methods of use
MX2012002766A (es) 2009-09-03 2012-04-02 Genentech Inc Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014204274A1 (ko) * 2013-06-21 2014-12-24 가톨릭대학교 산학협력단 류마티스 관절염 진단 또는 활성도 평가용 바이오마커
KR20150031405A (ko) * 2013-09-13 2015-03-24 인제대학교 산학협력단 Ｖｓｉｇ４를 이용한 난소암 치료제 스크리닝 방법
WO2016064229A1 (ko) * 2014-10-24 2016-04-28 가톨릭대학교 산학협력단 류마티스 관절염 관련 바이오마커
KR20180052104A (ko) * 2016-11-09 2018-05-17 아이씨엠 주식회사 Nkx3.2 단편을 유효성분으로 포함하는 관절염의 예방 또는 치료용 약학 조성물
KR20180052103A (ko) * 2016-11-09 2018-05-17 아이씨엠 주식회사 Nkx3.2 단편 및 이를 함유하는 약학 조성물
KR20200086627A (ko) * 2017-11-13 2020-07-17 더 멀티플 마이얼로머 리서치 파운데이션, 인크. 통합된, 분자, 체학, 면역요법, 대사, 후성적, 및 임상 데이터베이스
KR20210055856A (ko) * 2019-11-07 2021-05-18 가톨릭대학교 산학협력단 류마티스 관절염의 판누스 진단용 바이오마커 및 이의 이용

Also Published As

Publication number Publication date
EP3211094A3 (en) 2017-11-01
CN102597268B (zh) 2017-09-22
US8728730B2 (en) 2014-05-20
CA2772929A1 (en) 2011-03-11
JP2021019594A (ja) 2021-02-18
BR112012004777A2 (pt) 2019-09-24
MX2012002766A (es) 2012-04-02
MX353186B (es) 2018-01-05
JP6895718B2 (ja) 2021-06-30
JP5996429B2 (ja) 2016-09-21
IN2012DN02485A (enExample) 2015-08-28
HK1245341A1 (zh) 2018-08-24
WO2011028945A1 (en) 2011-03-10
CN107385034A (zh) 2017-11-24
JP2017000141A (ja) 2017-01-05
RU2014145058A (ru) 2016-05-27
CN107385034B (zh) 2021-08-17
CN102597268A (zh) 2012-07-18
EP2473637A1 (en) 2012-07-11
EP2473637A4 (en) 2013-05-01
US9822400B2 (en) 2017-11-21
JP2013503643A (ja) 2013-02-04
US20140341887A1 (en) 2014-11-20
RU2539112C2 (ru) 2015-01-10
EP2473637B1 (en) 2017-03-29
EP3211094A2 (en) 2017-08-30
US20110052488A1 (en) 2011-03-03
RU2012112822A (ru) 2013-10-10

Similar Documents

Publication Publication Date Title
JP6895718B2 (ja) 関節リウマチの治療、診断及びモニターするための方法
JP6271254B2 (ja) Ｂ細胞アンタゴニストに対する生物学的マーカー及び応答を予測するための方法
JP2013503643A5 (enExample)
JP5730576B2 (ja) 抗ｃｄ４０抗体による治療に対するｂ細胞リンパ腫の応答性を評価するための方法及び組成物
WO2012061620A1 (en) Methods for treating, diagnosing, and monitoring rheumatoid arthritis
JP2010527325A (ja) Ｂ細胞アンタゴニストに応答する関節リウマチを予測するバイオマーカー
KR101787768B1 (ko) 항-ｃｄ４０ 항체를 사용한 치료에 대한 ｂ-세포 림프종의 반응성 평가를 위한 방법
WO2008157282A1 (en) Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
MX2011003352A (es) Marcadores biologicos predictivos de la respuesta de la artritis reumatoide a antagonistas de linfotoxina.
HK1245341B (zh) 用於治疗、诊断和监控类风湿性关节炎的方法
HK1172061A (en) Methods for treating, diagnosing, and monitoring rheumatoid arthritis
HK1172061B (en) Methods for treating, diagnosing, and monitoring rheumatoid arthritis
HK1193437A (en) Biological markers and methods for predicting response to b-cell antagonists
HK1193437B (en) Biological markers and methods for predicting response to b-cell antagonists

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120402

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150902

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20161212

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170822

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180129

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20180424

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180129

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20170822

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20161212

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I